Stereotactic body radiation therapy versus intensity-modulated radiation therapy for prostate cancer: Comparison of toxicity

Journal of Clinical Oncology

Volumn 32, Issue 12, 2014, Pages 1195-1201

  Yu, James B ^a,b   Cramer, Laura D ^a   Herrin, Jeph ^a,c   Soulos, Pamela R ^a   Potosky, Arnold L ^d   Gross, Cary P ^a,b  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b YALE CANCER CENTER   (United States)

^c Health Research and Educational Trust   (United States)

^d GEORGETOWN UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AGED; ARTICLE; CANCER RADIOTHERAPY; GASTROINTESTINAL TOXICITY; GASTROINTESTINAL TRACT; GENOTOXICITY; HEALTH CARE COST; HUMAN; INTENSITY MODULATED RADIATION THERAPY; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; MEDICARE; PRIORITY JOURNAL; PROSTATE CANCER; RADIATION DOSE; RETROSPECTIVE STUDY; STEREOTACTIC BODY RADIATION THERAPY; URETHRITIS; URINARY TRACT OBSTRUCTION; URINE INCONTINENCE; UROGENITAL SYSTEM; VERY ELDERLY; ECONOMICS; METHODOLOGY; PROSTATE TUMOR; RADIOSURGERY; UNITED STATES;

AGED; AGED, 80 AND OVER; HUMANS; MALE; MEDICARE; PROSTATIC NEOPLASMS; RADIOSURGERY; RADIOTHERAPY DOSAGE; RADIOTHERAPY, INTENSITY-MODULATED; RETROSPECTIVE STUDIES; UNITED STATES;

EID: 84904515724     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2013.53.8652     Document Type: Article

References (30)

1. Bentzen SM, Wasserman TH: Balancing on a knife's edge: Evidence-based medicine and the marketing of health technology. Int J Radiat Oncol Biol Phys 72:12-14, 2008
2. Hodges JC, Lotan Y, Boike TP, et al: Cost-effectiveness analysis of stereotactic body radiation therapy versus intensity-modulated radiation therapy: An emerging initial radiation treatment option for organ-confined prostate cancer. J Oncol Pract 8:e31s-e37s, 2012
3. Sher DJ, Parikh R, Mays-Jackson S, et al: Cost-effectiveness analysis of SBRT versus IMRT for low-risk prostate cancer. Am J Clin Oncol [epub ahead of print on December 27, 2012]
4. Cho LC, Timmerman R, Kavanagh B: Hypofractionated external-beam radiotherapy for prostate cancer. Prostate Cancer 2013:103547, 2013
5. Jabbari S, Weinberg VK, Shinohara K, et al: Equivalent biochemical control and improved prostate-specific antigen nadir after permanent prostate seed implant brachytherapy versus high-dose three-dimensional conformal radiotherapy and high-dose conformal proton beam radiotherapy boost. Int J Radiat Oncol Biol Phys 76:36-42, 2010
6. Zaorsky NG, Studenski MT, Dicker AP, et al: Stereotactic body radiation therapy for prostate cancer: Is the technology ready to be the standard of care? Cancer Treat Rev 39:212-218, 2013
7. Webb S: Conformal intensity-modulated radiotherapy (IMRT) delivered by robotic linac: Testing IMRT to the limit? Phys Med Biol 44:1639-1654, 1999
8. King CR, Brooks JD, Gill H, et al: Stereotactic body radiotherapy for localized prostate cancer: Interim results of a prospective phase II clinical trial. Int J Radiat Oncol Biol Phys 73:1043-1048, 2009
9. Freeman DE, King CR: Stereotactic body radiotherapy for low-risk prostate cancer: Five-year outcomes. Radiat Oncol 6:3, 2011
10. Chen LN, Suy S, Uhm S, et al: Stereotactic body radiation therapy (SBRT) for clinically localized prostate cancer: The Georgetown University experience. Radiat Oncol 8:58, 2013
11. Aneja S, Pratiwadi RR, Yu JB: Hypofractionated radiation therapy for prostate cancer: Risks and potential benefits in a fiscally conservative health care system. Oncology (Williston Park) 26:512-518, 2012
12. Makarov DV, Yu JB, Desai RA, et al: The association between diffusion of the surgical robot and radical prostatectomy rates. Med Care 49:333-339, 2011
13. Siegel R, Naishadham D, Jemal A: Cancer statistics, 2013. CA Cancer J Clin 63:11-30, 2013
14. The National Association for Proton Therapy, 2012. http://www.proton- therapy.org
15. Yu JB, Soulos PR, Herrin J, et al: Proton versus intensity-modulated radiotherapy for prostate cancer: Patterns of care and early toxicity. J Natl Cancer Inst 105:25-32, 2013
16. Shahinian VB, Kuo YF, Gilbert SM: Reimbursement policy and androgen-deprivation therapy for prostate cancer. N Engl J Med 363:1822-1832, 2010
17. Elixhauser A, Steiner C, Harris DR, et al: Comorbidity measures for use with administrative data. Med Care 36:8-27, 1998 (Pubitemid 128456396)
18. Rubin DB: Bias reduction using Mahalanobismetric matching. Biometrics 36:293-298, 1980
19. Clinicaltrials.gov: Radiation Therapy in Treating Patients With Prostate Cancer (NCT01434290), 2013. http://clinicaltrials.gov/show/NCT01434290
20. Clinicaltrials.gov: Radiation Hypofractionation Via Extended Versus Accelerated Therapy (HEAT) For Prostate Cancer (NCT01794403), 2013. http://clinicaltrials.gov/ct2/show/NCT01794403
21. Clinicaltrials.gov: Prostate Advances in Comparative Evidence (NCT01584258), 2013. http://www.clinicaltrials.gov/ct2/show/NCT01584258
22. Current Controlled Trials: Phase III Study of Hypofractionated Radiotherapy of Intermediate Risk Localized Prostate Cancer (ISRCTN45905321), 2013. http://www.controlled-trials.com/ISRCTN45905321
23. King CR, Brooks JD, Gill H, et al: Long-term outcomes from a prospective trial of stereotactic body radiotherapy for low-risk prostate cancer. Int J Radiat Oncol Biol Phys 82:877-882, 2012
24. Zelefsky MJ, Fuks Z, Hunt M, et al: High-dose intensity modulated radiation therapy for prostate cancer: Early toxicity and biochemical outcome in 772 patients. Int J Radiat Oncol Biol Phys 53:1111-1116, 2002 (Pubitemid 34787844)
25. Loblaw A, Cheung P, D'Alimonte L, et al: Prostate stereotactic ablative body radiotherapy using a standard linear accelerator: Toxicity, biochemical, and pathological outcomes. Radiother Oncol 107:153-158, 2013
26. Gray PJ, Paly JJ, Yeap BY, et al: Patient-reported outcomes after 3-dimensional conformal, intensity-modulated, or proton beam radiotherapy for localized prostate cancer. Cancer 119:1729-1735, 2013
27. King CR, Collins S, Fuller D, et al: Health-related quality of life after stereotactic body radiation therapy for localized prostate cancer: Results from a multi-institutional consortium of prospective trials. Int J Radiat Oncol Biol Phys 87:939-945, 2013
28. Odrazka K, Dolezel M, Vanasek J, et al: Time course of late rectal toxicity after radiation therapy for prostate cancer. Prostate Cancer Prostatic Dis 13:138-143, 2010
29. Fuller DB, Naitoh J, Lee C, et al: Virtual HDR CyberKnife treatment for localized prostatic carcinoma: Dosimetry comparison with HDR brachytherapy and preliminary clinical observations. Int J Radiat Oncol Biol Phys 70:1588-1597, 2008 (Pubitemid 351417778)
30. Vainshtein J, Abu-Isa E, Olson KB, et al: Randomized phase II trial of urethral sparing intensity modulated radiation therapy in low-risk prostate cancer: Implications for focal therapy. Radiat Oncol 7:82, 2012